BSEM-002

BSEM-002 is an investigational **mesenchymal stem cell therapy** being developed by BioStem Technologies for **acute respiratory distress syndrome**. Publicly available pipeline summaries describe it as an **umbilical cord tissue native MSCs therapy**, implying a cell-based regenerative medicine product derived from umbilical cord tissue. Its proposed therapeutic rationale is consistent with MSC-based approaches in ARDS, which aim to modulate dysregulated inflammation and support tissue repair in injured lung tissue, but the specific molecular target profile and definitive mechanism of action for BSEM-002 have not been clearly disclosed in the accessible sources reviewed. Available evidence suggests the program remained at a **preclinical or pending early development** stage rather than in advanced clinical development.

Other names

Umbilical cord tissue native MSCs therapy